By Spondylitis Association of America
On March 28, 2019, the U.S. FDA announced the approval of the TNF inhibitor, certolizumab pegol (CIMZIA®) for the treatment for non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first, and currently only biologic agent to gain approval for nr-axSpA in the U.S., providing those living with the condition access to a new class of medication.
On Saturday, April 27, from 10 am to 2 pm, the U.S. Drug Enforcement Administration will be hosting their 17th National Pill Take Back Event alongside local community members and organizations. The best part is that the service is free and anonymous and allows for the public to drop off unused medications with no questions asked.
By Brent Wells, DC
As someone suffering from spondyloarthritis, you know just how exhausting it can be to get into a comfortable position at night. Then, when you finally do find something that allows you to rest, pain and stiffness can shake you back awake in the middle of the night.
Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. In this installment, we asked our online community, “Which medical professional has the most impact on managing your spondylitis symptoms? Rheumatologist, Primary Care Physician, Osteopathic Physician, Functional Medicine, Physical Therapist, Pain Management Specialist, or Psychologist?"
The purpose of the trial is to study the safety and efficacy of Tildrakizumab in those with psoriatic arthritis (PsA), ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA).
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.